Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

The approval marks first indication for Keytruda in MPM in the US, MPM is a rare, aggressive cancer around the lining of the lungs and chest Wednesday, the FDA approved Merck & Co Inc’s MRK ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

8 analysts have shared their evaluations of Merck & Co MRK during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

Blockbuster cancer drug combined with chemotherapy improved survival rates in a Phase 3 trial Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...